论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
Authors Liu H, Pan Y, Han X, Liu J, Li R
Received 4 June 2016
Accepted for publication 18 August 2016
Published 23 May 2017 Volume 2017:10 Pages 2701—2709
DOI http://doi.org/10.2147/OTT.S114318
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr Yao Dai
Abstract: MicroRNAs, a group of posttranscriptional regulators of numerous genes,
are active participators during the development and progression of ovarian cancer
(OC). This study confirmed for the first time that miR-216a was gradually
increased in normal, benign, borderline, and OC tissues and that its expression
was significantly upregulated in all OC cell lines. Analysis of its clinical
association demonstrated that elevated expression of miR-216a was associated
with lymph node metastasis and advanced FIGO stage and was correlated with the
poor survival of OC patients. Functional experiments showed that miR-216a
overexpression potentiated the migration and invasion of CAOV3 cells while
miR-216a inhibition reduced the migration and invasion of SKOV-3 cells. Both
gain and lose of function assay showed that miR-216a promoted
epithelial–mesenchymal transition (EMT) of OC cells. Mechanistically,
phosphatase and tensin homolog (PTEN) was confirmed as a direct downstream
target of miR-216a in OC cells. Alerting miR-216a expression in OC cells
modulated the activity of PTEN/AKT pathway in OC cells. Furthermore, this study
confirmed that miR-216a exerted its promoting effects on the metastatic
behaviors and EMT of OC cells by inhibiting PTEN/AKT pathway. Taken together,
this study demonstrates that miR-216a exerts a promoting role in the metastasis
of OC and can serve as a promising biomarker and an attractive therapeutic
target of OC.
Keywords: miR-216a,
ovarian cancer, PTEN, epithelial-mesenchymal transition, metastasis, biomarker